Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial.

@article{Karthaus2006DalteparinFP,
  title={Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial.},
  author={Meinolf Karthaus and Albrecht Kretzschmar and Hendrik Kroening and Mikhail Y. Biakhov and David Irwin and Norbert Marschner and Coba Slabber and George Fountzilas and August Garin and N G F Abecasis and W Baronius and Guenther G. Steger and Thomas Suedhoff and Carla Giorgetti and Peter Reichardt},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2006},
  volume={17 2},
  pages={289-96}
}
BACKGROUND Cancer patients receiving chemotherapy experience thromboembolic complications associated with the use of long-term indwelling central venous catheters (CVCs). This prospective, double-blind, placebo-controlled, multicenter study evaluated whether prophylactic treatment with a low molecular weight heparin could prevent clinically relevant catheter-related thrombosis. PATIENTS AND METHODS Patients with cancer undergoing chemotherapy for at least 12 weeks (n=439) were randomly… CONTINUE READING